Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind randomized trial of zaltoprofen in diffuse and unresectable tenosynovial giant cell tumor
jRCT2091220284Phase 2Completed
- Sponsor
- Kanazawa University Hospital
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in tenosynovial giant cell tumor (TGCT) comparing Zaltoprofen with Placebo (2 arms). Primary endpoint: Progression-free rate at 48 weeks. Started Apr 2017; status: completed.
02
Drugs
zaltoprofen
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on jRCT2091220284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220284.